Elicio Therapeutics NASDAQ:ELTX Elicio is committed to transforming the lives of patients and their families by re-engineering the body’s immune response to cancer. By combining expertise in materials science and immunology, Elicio is engineering potent vaccines and immuno-therapies for an array of aggressive cancers. The Elicio Amphiphile platform enables precise targeting and delivery of immunogens directly to the lymphatic system, the “brain center” of the immune response, to significantly amplify and enhance the body’s own system of defenses, to defeat cancer and stop its recurrence. This substantially enhanced anti-tumor functionality and long-term protective memory could unlock the full potential of the human immune response to eliminate cancer. Elicio's lead Amphiphile vaccines targeting pancreatic, colorectal, and head and neck cancer will begin initial patient studies in early 2020. Elicio was founded to expand and apply the ground-breaking Amphiphile technology invented and developed in the labs of Darrell Irvine Ph.D., Professor of Biological Engineering and Materials Sciences and Howard Hughes Investigator, at the Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology. Preclinical studies have demonstrated that Elicio’s Amphiphile vaccines target and concentrate in the lymph nodes resulting in unprecedented tumor-specific immune responses and durable cures of aggressive tumor models in mice.

Location: Boston, Massachusetts, United States | Website: https://elicio.com/ | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing